Christopher Sarchi
Fortune : 2 M $ au 31/05/2026
Fortune : 2 M $ au 31/05/2026
Christopher Sarchi is currently Chief Commercial Officer at Bicara Therapeutics, Inc. since 2026 and Chief Commercial Officer at Replimune Group, Inc. since 2022.
Former positions include Director-Oncology Regional Sales at Genentech, Inc. from 2010 to 2013 and Head-Commercial Oncology US Region at Sanofi.
Education includes undergraduate studies at the University of Maine.
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
REPLIMUNE GROUP, INC. 0,23 % | 01/06/2026 | 180 962 ( 0,23 % ) | 2 M $ | 31/05/2026 |
| Sociétés | Poste | Début |
|---|---|---|
| REPLIMUNE GROUP, INC. | Corporate Officer/Principal | 01/12/2022 |
| BICARA THERAPEUTICS INC. | Corporate Officer/Principal | 08/05/2026 |
| Sociétés | Poste | Fin |
|---|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Corporate Officer/Principal | 01/01/2013 |
| SANOFI | Corporate Officer/Principal | - |
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
| Entreprise privées | 5 |
|---|---|
Genentech, Inc.
Genentech, Inc. BiotechnologyHealth Technology Operates as a biotechnology company that develops medicines for cancer peoples | Health Technology |
Sanofi
Sanofi Pharmaceuticals: MajorHealth Technology Engages in research, development and production of pharmaceuticals & vaccines | Health Technology |
University of Maine
University of Maine Other Consumer ServicesConsumer Services Functions as a College/University | Consumer Services |
Replimune Group, Inc.
Replimune Group, Inc. BiotechnologyHealth Technology Develops oncolytic immunotherapies | Health Technology |
Bicara Therapeutics, Inc.
Bicara Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Operates as a clinical-stage biopharmaceutical company that develops and sells therapeutics for tumors | Health Technology |
Sélectionnez votre édition
Toutes les informations financières adaptées au niveau national